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Objectives. We sought to assess the influence of baseline lipid
levels on coronary event rates and the effectiveness of pravastatin
therapy in the Cholesterol And Recurrent Events (CARE) study.
Background. The CARE study cohort provided a relatively
unique opportunity to examine the relation between lipid levels
and clinical events in a post–myocardial infarction (MI) popula-
tion with relatively low cholesterol and low density lipoprotein
(LDL) cholesterol values.
Methods. There were 4,159 patients with a previous infarct and
a total cholesterol level <240 mg/dl, LDL cholesterol level 115 to
174 mg/dl and triglyceride level <350 mg/dl randomly allocated to
placebo (n 5 2,078) or pravastatin 40 mg/day (n 5 2,081). Time
to either coronary death or nonfatal MI (primary end point) or to
the secondary end point, which included undergoing a coronary
revascularization procedure, was determined as a function of
baseline lipids (total, LDL, high density lipoprotein [HDL] cho-
lesterol and triglyceride levels).
Results. Quartile analysis indicated important effects for LDL
cholesterol, in which a higher LDL was associated with greater
cardiac event rates (in the placebo group, every 25-mg/dl incre-
ment in LDL was associated with a 28% increased risk [5% to
56%, p 5 0.015]) in the primary event. The differential event rates
with respect to baseline LDL cholesterol for placebo and prava-
statin groups reduced the difference in clinical outcomes at lower
LDL cholesterol levels. In both the placebo and pravastatin
groups, an inverse relation between baseline HDL cholesterol and
cardiac events was observed (10 mg/dl lower baseline HDL
cholesterol level was associated with a 10% [0% to 19%, p 5 0.046]
increase in coronary death or nonfatal MI).
Conclusions. Within the LDL cholesterol levels in CARE (115 to
174 mg/dl), baseline values influenced both the risk of events in
the placebo group as well as the clinical effectiveness of pravasta-
tin therapy.
(J Am Coll Cardiol 1999;33:125–30)
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Epidemiologic studies have quantified the importance of ele-
vated plasma cholesterol as a risk factor for the development
of first (1–4) as well as recurrent coronary heart disease events
(3–6). This relation between cholesterol, particularly low den-
sity lipoprotein (LDL) cholesterol, and coronary risk is non-
linear; the absolute and relative increases in risk are greater at
the higher end of the cholesterol distribution (1,7,8). Before
the development of 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (HMGs), there was evidence that a cho-
lesterol reduction with either dietary measures, an intestinal
bypass procedure or treatment with lipid-lowering agents of
moderate efficacy could reduce this risk of coronary heart
disease events in hypercholesterolemic patients with existing
coronary disease (9,10). However, offsetting questions regard-
ing the magnitude of this effect, compliance issues and con-
cerns of possible adverse effects of long-term pharmacologic
therapies limited their implementation (11,12).
Randomized, controlled clinical trials with HMGs in hyper-
cholesterolemic patients without (13) and with (14) overt
coronary disease have proved definitively that these agents
reduce coronary heart disease events (i.e., deaths, myocardial
infarction [MI] and the need for coronary revascularization
procedures) without an offsetting increase in noncardiovascu-
lar events. Further analysis of the Scandinavian Simvastatin
Survival Study (4S) demonstrated that within the range of total
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cholesterol (5.5 to 8.0 mmol/liter, 212 to 306 mg/dl) the relative
risk reduction of these major coronary events attributed to
simvastatin was not influenced by the baseline cholesterol
value (15).
The CARE trial was a randomized, placebo-controlled trial
testing the effectiveness of pravastatin (40 mg) on the inci-
dence of coronary heart disease events in a broad group of
survivors of MI with a total cholesterol level ,240 mg/dl (mean
209) (16). The trial demonstrated an overall benefit of prava-
statin therapy with a 24% reduction in fatal coronary heart
disease deaths and nonfatal MI (95% confidence interval [CI]
9% to 36%) and a 24% (95% CI 13% to 33%) reduction in the
end point of major coronary events used for prespecified
subgroup analysis (16). Thus, the CARE study extended the
benefits of cholesterol-lowering therapy to an even broader
group of patients with average cholesterol values. The present
analysis of CARE data was conducted to determine the
influence of baseline lipid values on the coronary event rates of
the groups assigned to placebo and pravastatin, with particular
emphasis on the patients with lower total and LDL cholesterol
values, a cohort underrepresented in previous trials.
Methods
The CARE study design and results have been reported
previously (16,17). In brief, 4,159 survivors of MI (average 3 to
20 months) with a total cholesterol level ,240 mg/dl, an LDL
cholesterol level between 115 and 174 mg/dl and a fasting
triglyceride level ,350 mg/dl were randomized to conventional
therapy plus either placebo or pravastatin 40 mg/day. Lipid
levels were determined by a central core laboratory from an
average of at least two samples. Additional inclusion and
exclusion criteria have been delineated (17). The study was
designed to have a median follow-up period of 5 years and had
as its primary end point death attributed to coronary heart
disease or a nonfatal MI. A secondary end point of major
coronary events (fatal coronary heart disease, nonfatal MI,
coronary artery bypass surgery or angioplasty) was constructed
to assess therapeutic efficacy within subgroups (16).
Quartile ranges were constructed based on the distribution
of prerandomization values for total, LDL and high density
lipoprotein (HDL) cholesterol levels as well as triglyceride
levels. For the purpose of comparison, a post-hoc analysis was
conducted which utilized the lipid eligibility criteria employed
in 4S (total cholesterol $212 mg/dl and triglyceride ,220
mg/dl) to designate CARE patients as either “4S lipid-eligible”
or “4S lipid-ineligible.”
All analyses were performed on an intention-to-treat basis,
and p values were two-sided. The comparability of baseline
characteristics across baseline lipid levels (lower vs. highest
quartile) was ascertained using standard normal tests for
continuous variables and the chi-square test for categoric
variables. All hypothesis testing and all risk reductions with
their confidence intervals were assessed using the Cox propor-
tional hazards model. Kaplan-Meier survival curves for the
control and pravastatin groups were calculated (18).
The impact of the baseline lipid level on the primary and
major coronary event end points in CARE was assessed using
a Cox proportional hazards model, with time to the event as
the dependent variable. The role of baseline lipids as a risk
factor for the occurrence of either the primary or secondary
end point was obtained through interaction models. The
models attempted to identify interactions in two ways. The first
procedure included the baseline lipid level as an independent
variable, which allowed an assessment of the linear effect that
baseline lipids would have on the end point. The second
interaction analysis examined the impact of lipids on the end
point by including three indicator variables (the lowest quartile
is the referent quartile) simultaneously in the Cox proportional
hazards model, which allowed not only the effect of lipids to be
different from quartile to quartile, but also the effect of therapy
in adjusting these quartile effects to vary across lipid quartiles.
Relations between baseline lipid values and event rates and
therefore treatment effect were also estimated using a regres-
sion model.
Results
During the course of the trial, the pravastatin group had a
reduction of total cholesterol by 20%, LDL cholesterol by 28%
and triglyceride level by 14%, and HDL cholesterol increased
by 5% as compared with the placebo group. The frequency of
the primary end point was 13.2% in the placebo group and
10.2% in the pravastatin group (relative risk reduction 24%,
p 5 0.003). Major coronary events (primary end point or
myocardial revascularization) occurred in 26.4% of the pla-
cebo group and 20.1% in the pravastatin group (relative risk
reduction 24%, p , 0.001).
Within the cholesterol range of the CARE patients (159 to
239 mg/dl), the baseline value did not significantly influence
the risk of experiencing a coronary event subsequent to
randomization (Fig. 1). Even when the analysis was limited to
the 2,078 placebo-assigned patients a significant relation be-
tween baseline cholesterol and the primary study end point was
not detected (11% relative risk for coronary heart disease
death or nonfatal MI for a 25-mg/dl increase in baseline
cholesterol, 95% CI 27 to 32, p 5 0.246). Similarly, expanding
this coronary end point to also include revascularization pro-
cedures did not result in a significant influence of baseline
cholesterol and coronary event risk in the placebo group (6%
Abbreviations and Acronyms
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relative risk for every 25-mg/dl cholesterol increment, 95% CI
26% to 20%, p 5 0.315) (Fig. 1).
However, there was a significant relation between the
baseline LDL cholesterol level (range 115 to 174 mg/dl) and
the risk of experiencing a coronary event. For the entire cohort
(i.e., patients in both treatment arms combined into a single
group), for every 25-mg/dl increment of baseline LDL choles-
terol, there was an 18% increase in the relative risk of coronary
death or MI (95% CI 1% to 37%, p 5 0.034). In the overall
group, the risk of experiencing the expanded coronary end
point for a 25-mg/dl increase in baseline LDL cholesterol was
22% (95% CI 2% to 46%, p 5 0.028). This increase in risk with
higher baseline LDL cholesterol was mainly attributed to the
placebo-assigned patients. In the placebo group, a 25-mg/dl
increment of baseline LDL cholesterol was associated with a
28% increased risk of coronary death or MI (95% CI 5% to
56%, p 5 0.015). Similarly, for the major coronary event end
points (already defined), there was a significant influence of
baseline LDL cholesterol on coronary events only in the
placebo group, with every 25-mg/dl increment in LDL choles-
terol associated with an 18% increased risk (95% CI 3% to
36%, p 5 0.021) (Fig. 2). For pravastatin-assigned patients, a
25-mg/dl increase in baseline LDL cholesterol was not associ-
ated with a significant increase in the risk (6%) of either
coronary death or nonfatal MI (95% CI 216% to 34%, p 5
NS) or the risk (2%) of the expanded end point, which includes
coronary revascularization procedures (95% CI 213% to 20%,
p 5 NS). This trend toward a differential influence of baseline
LDL cholesterol in the placebo and pravastatin groups on
coronary event rates (interaction p 5 0.226) resulted in a
convergence of event rates between the placebo and pravasta-
tin groups at the lower LDL cholesterol levels.
Designating by quartiles for higher LDL cholesterol levels,
as anticipated, resulted in a concomitantly higher total choles-
terol level. However, HDL cholesterol did not vary across LDL
cholesterol quartiles, and fasting triglyceride levels decreased
with increasing LDL cholesterol quartiles (Table 1). The
patient characteristics were, for the most part, comparable
across LDL cholesterol quartiles, except that the lowest quar-
tile patients were slightly older, had a higher prevalence of
diabetes and were predominantly men than the higher LDL
quartile patients (Table 1). At the lowest LDL quartile (n 5
1,046, range 115 to 127 mg/dl, median 121), the risk reduction
with pravastatin for the primary end point was only 9% (95%
CI 238% to 33%) and, similarly, for all major coronary events
it was 7% (95% CI 229% to 20%) (Fig. 2).
In the combined treatment arms, there was an important
inverse relation between baseline values for HDL cholesterol
and coronary event rates. For each 10-mg/dl decrement in the
baseline HDL cholesterol value, there was an 11% greater
likelihood of experiencing a coronary death or nonfatal MI
(95% CI 0% to 23%, p 5 0.049). When major coronary events
were considered as the end point, the influence of baseline
HDL cholesterol was similar, with a 10% increase in the risk of
these coronary events (95% CI 3% to 19%, p 5 0.007) for each
10-mg/dl decrement in baseline HDL cholesterol of the com-
bined groups. This influence of baseline HDL cholesterol on
coronary events was similar in the placebo and pravastatin
groups, with no trend for an interaction. In each quartile of
HDL cholesterol, the benefits of pravastatin were comparable
(Fig. 3).
Within the range of fasting triglyceride levels (90 to 350
mg/dl), no statistically significant linear relation between base-
line levels and the primary or expanded end points was
observed in either the overall cohort or within the treatment
Figure 1. Relation of quartiles of baseline total cholesterol and
subsequent coronary events for placebo (line with circles) and prava-
statin (line with squares) groups. The upper two lines are the
cumulative event rates for the secondary end point of either fatal
coronary heart disease (CHD), nonfatal MI, coronary artery bypass
graft surgery or angioplasty. The lower two lines are the primary
cumulative event rates for either coronary heart disease death or
nonfatal MI.
Figure 2. Relation of quartiles of LDL cholesterol and subsequent
coronary events for placebo (line with circles) and pravastatin (line
with squares) groups. The upper two lines are the cumulative event
rates for the secondary end point of either fatal coronary heart disease
(CHD), nonfatal MI, coronary artery bypass graft surgery or angio-
plasty. The lower two lines are the primary cumulative event rates for
either coronary heart disease death or nonfatal MI.
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groups. Although the risk reduction for coronary events was
not significantly altered by baseline triglycerides, the lowest
two quartiles demonstrated the greater risk reduction with
pravastatin (risk reduction 30.3%, 28.8%, 14.1% and 18.5% for
expanded end points, lowest to highest triglyceride quartile,
respectively) (Fig. 4).
Utilizing 4S lipid criteria, 34% of the CARE population
(n 5 1,409) could have been considered as eligible and the
majority (66%, n 5 2,750) would have had either cholesterol
values too low or triglyceride values too high, or both, to have
been eligible for that study. This construction for 4S lipid-
eligible and lipid-ineligible subgroups within CARE produced
groups that were comparable with respect to age, ejection
fraction, history of hypertension, previous coronary artery
bypass graft surgery or angioplasty and use of aspirin (Table 2).
However, the 4S lipid-eligible group had a lower percentage of
men and diabetics (Table 2). By design, the cholesterol values
Figure 3. Relation of quartiles of HDL cholesterol and subsequent
coronary events for placebo (line with circles) and pravastatin (line
with squares) groups. The upper two lines are the cumulative event
rates for the secondary end point of either fatal coronary heart disease
(CHD), nonfatal MI, coronary artery bypass graft surgery or angio-
plasty. The lower two lines are the primary cumulative event rates for
either coronary heart disease death or nonfatal MI.
Figure 4. Relation of quartiles of triglycerides and subsequent coro-
nary events for placebo (line with circles) and pravastatin (line with
squares) groups. The upper two lines are the cumulative event rates
for the secondary end point of either fatal coronary heart disease
(CHD), nonfatal MI, coronary artery bypass graft surgery or angio-
plasty. The lower two lines are the primary cumulative event rates for
either coronary heart disease death or nonfatal MI.
Table 1. Low Density Lipoprotein Quartile
I (n 5 1,046) II (n 5 1,044) III (n 5 1,053) IV (n 5 1,016) p Value
Lipids
LDL cholesterol (mg/dl) 120.9 6 3.6 132.3 6 3.2 143.2 6 3.3 158.8 6 6.5 By design
Total cholesterol (mg/dl) 191.9 6 13.7 202.9 6 12.2 213.7 6 11.0 226.1 6 8.8 , 0.001
HDL cholesterol (mg/dl) 38.7 6 10.3 38.7 6 9.3 39.4 6 8.6 38.6 6 7.8 NS
Triglycerides (mg/dl) 161.4 6 69.0 159.8 6 65.0 156.1 6 59.1 144.7 6 46.7 , 0.001
Baseline Characteristics
Age (yrs) 59.0 6 9.5 58.7 6 9.3 58.9 6 8.9 57.9 6 9.5 0.026
Gender, male 88.5 86.4 84.1 85.6 0.027
LVEF (%) 53.0 6 11.9 53.1 6 12.3 53.1 6 12.2 52.9 6 11.7 NS
History of diabetes 16.1 17.1 13.0 10.0 , 0.001
History of hypertension 41.9 44.0 44.9 39.8 NS
Previous CABG or PTCA 55.3 53.4 53.9 53.4 NS
Angina 22.0 19.8 21.8 19.2 NS
Aspirin 84.2 81.3 82.3 85.1 NS
Beta-blockers 40.6 41.0 38.8 38.1 NS
ACE inhibitors 14.8 14.6 13.7 13.6 NS
Calcium channel blockers 37.1 38.2 41.2 40.6 NS
Nitrates 31.9 31.4 35.3 31.2 NS
Ever smoked (%) 60.8 63.0 61.6 60.5 NS
Current smoking (%) 15.5 15.6 15.6 17.8 NS
Data are presented as the mean value 6 SD or number (%) of patients. ACE 5 angiotensin-converting enzyme;
CABG 5 coronary artery bypass graft surgery; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; LVEF 5
left ventricular ejection fraction; PTCA 5 percutaneous transluminal coronary angioplasty.
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of these two groups within CARE differed, with total choles-
terol levels higher (224 6 7.7 vs. 201 6 15 mg/dl) and
triglyceride levels lower (146 6 40 vs. 161 6 69 mg/dl) in the
CARE patients who were 4S lipid-eligible as compared lipid-
ineligible.
For the placebo group, this selection of 4S lipid criteria
resulted in a greater likelihood of experiencing either coronary
death or nonfatal MI (15.4% [109 of 710 patients] vs. 12.0%
[116 of 1,368 patients], 4S lipid-eligible vs. ineligible). In the
pravastatin group the event rates in both the 4S lipid-eligible
(9.8% [136 of 1,382 patients]) and lipid-ineligible (10.7% [75 of
699 patients]) subgroups were both lower than that in the
placebo group. The expanded end point rates, which included
coronary revascularization procedures, were also more fre-
quent in placebo-assigned 4S lipid-eligible (28.2% [200 of 710
patients]) and lipid-ineligible groups (25.4% [348 of 1,368
patients]) than in their respective pravastatin groups (21.2%
[148 of 699] vs. 20.4% [282 of 1,382]). Therefore, in CARE
patients, the risk reduction of coronary deaths and MI with
pravastatin therapy tended to be of a greater magnitude in the
4S lipid-eligible (risk reduction 32% [9% to 49%]) than in the
4S lipid-ineligible patients (risk reduction 18% [22 to 35])
(Fig. 5). The risk reduction for the expanded coronary end
point was 26% (95% CI 9% to 40%, p 5 0.005) and 21% (95%
CI 8% to 33%, p 5 0.003) for the 4S lipid-eligible and
lipid-ineligible groups, respectively. Indeed, in a smaller (n 5
574) CARE cohort meeting 4S lipid and other inclusion
criteria (age ,70 years, no MI in past 6 months, no past
cerebral vascular event or current antiarrhythmic therapy), a
striking 48% risk reduction (95% CI 11% to 70%) was
observed for coronary death or MI, with a 20% risk reduction
(95% CI 3% to 34%) observed in the remaining 3,555 non-4S
eligible CARE patients.
Discussion
CARE and 4S. Taken together, the 4S and CARE studies
definitively show the value of pravastatin and simvastatin for
an extremely broad range of patients with prevalent coronary
artery disease. Because the risk attributed to cholesterol is not
linear, but increases sharply over the higher ranges, a greater
benefit of cholesterol reduction would be anticipated in pa-
tients with the most severe elevations in cholesterol. In 4S, the
patients who received placebo who were within the highest
quartiles for either total cholesterol or LDL cholesterol ($282
and 207 mg/dl, respectively) experienced ;20% more major
coronary events than the patients who received placebo in the
lowest quartiles (total cholesterol ,241 and LDL cholesterol
#170 mg/dl). A quartile analysis for baseline total and LDL
cholesterol within 4S for the effectiveness of simvastatin
showed a relatively uniform clinical benefit of therapy within
those subgroups over the range of values in their study (15).
Approximately one-third of CARE patients had lipid values
within the 4S range. The analysis of the overlapping lipid-
eligible patients in CARE and 4S underscores that in patients
with documented coronary artery disease and total cholesterol
.212 mg/dl, substantial clinical benefits can be anticipated
with the use of either simvastatin or pravastatin. In the
two-thirds of CARE patients whose total cholesterol values
were lower than those of 4S patients, a clinically important
18% reduction in coronary deaths and nonfatal MI was
demonstrated with pravastatin therapy in survivors of MI who
had modern management.
Patients with LDL cholesterol. However, our analysis sug-
gests that the efficacy of HMG therapies in patients with
coronary artery disease with low baseline LDL cholesterol
values may be more limited. The quartile analysis for LDL
cholesterol revealed only a modest, nonsignificant reduction in
coronary events in the lowest quartile (115 , 127 mg/dl). As
previously presented in the lowest quintile (LDL cholesterol
,125 mg/dl) of CARE, no beneficial trend was observed with
pravastatin (16). It should be emphasized that with the declin-
ing serum cholesterol levels in many patients (19) and with
aging (20) that many coronary events occur in individuals with
“desirable” total cholesterol and LDL values (21). Indeed, a
Figure 5. Kaplan-Meier estimates of the incidence of coronary heart
disease death or nonfatal MI in subgroups of CARE patients, con-
structed by baseline lipids for eligibility in 4S. RR 5 relative risk
reduction.
Table 2. Within the Cholesterol and Recurrent Events Trial: Lipids
in Scandinavian Simvastatin Survival Study
Eligible*
(n 5 1,409)
Noneligible
(n 5 2,750) p Value
Age (yrs) 58.7 6 9.2 58.6 6 9.4 NS
Gender, male 1,127 (80.0%) 2,456 (89.3%) , 0.001
LVEF (%) 53.2 6 12 52.9 6 12.1 NS
History of diabetes 150 (10.7%) 436 (15.9%) , 0.001
History of hypertension 596 (43.3%) 1.177 (42.8%) NS
Previous CABG or PTCA 762 (54.1%) 1,482 (53.9%) NS
Angina 289 (20.5%) 572 (20.8%) NS
Aspirin 1,178 (83.6%) 2,284 (83.1%) NS
Beta-blockers 526 (37.3%) 1,123 (40.8%) 0.029
ACE inhibitors 196 (13.9%) 393 (14.3%) NS
Calcium channel blockers 592 (42.0%) 1,040 (37.8%) 0.009
Nitrates 449 (31.9%) 902 (32.8%) NS
*Lipid eligibility according to the Scandinavian Simvastatin Survival Study:
total cholesterol level $212 mg/dl and triglyceride level ,220 mg/dl. Data are
presented as the mean value 6 SD or number (%) of patients. Abbreviations as
in Table 1.
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frequent exclusion for CARE was an LDL value #114 mg/dl
(17). This finding of an apparent reduction in the efficacy of
HMG therapies in patients with lower LDL levels and coro-
nary artery disease has major public health implications con-
cerning the appropriate therapies for a substantial group of
patients.
Patients with coronary artery disease despite low total
cholesterol and LDL cholesterol tend to have relatively low
HDL cholesterol and are more likely to be diabetic (17,21).
Indeed, the mean HDL cholesterol level in CARE of 39 mg/dl
was lower than the mean value of 46 mg/dl in 4S. Other less
well-characterized risk factors are likely to have a more
pronounced role in the pathogenesis of their coronary athero-
sclerosis. Our data, although hypothesis generating and not
definitive, indicate that further lowering of LDL cholesterol in
this understudied group with low LDL cholesterol and coro-
nary artery disease may not have a major clinical impact.
Meta-analyses of secondary prevention trials of cholesterol-
lowering therapies suggest that there is less benefit with lower
baseline cholesterol values (22). The Long-term Intervention
with Pravastatin in Ischemic Disease (LIPID) study, with 25%
of its 9,014 patients having a total cholesterol and LDL
cholesterol level of 196 and 131 mg/dl or less, respectively, will
add a great deal of information on the effectiveness of statins
in patients in this range (23). Major clinical trials exploring the
alternative and not mutually exclusive approaches of pharma-
cologically raising HDL cholesterol in this patient group are
under way (24,25). The other classic risk factors and new
potentially modifiable risk factors, such as elevated homocys-
teine levels (26) and other yet to be identified atherosclerotic
risk factors, may have a greater influence in this group with low
LDL cholesterol and coronary disease.
Conclusions. The additive and interactive nature of ath-
erosclerotic risk factors complicates the use of arbitrary thresh-
old values for the initiation of therapy. In patients with
clinically apparent coronary artery disease, the greater likeli-
hood of a recurrent cardiovascular event justifies an intensive
individual approach to their risk factor management. Although
the CARE study demonstrates that therapy would be antici-
pated to reduce clinical events in a broad group of patients
with coronary artery disease who receive modern management,
the study also indicates that the cohort with atherosclerosis and
low LDL cholesterol levels appears to benefit less with this
form of therapy and constitutes an important focus for new
investigative efforts.
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